INTS Intensity Therapeutics, Inc.
Healthcare$4.68-0.64%ClosedMarket Cap: $8.8M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
11.96
P/S
0.00
EV/EBITDA
0.15
DCF Value
$0.83
FCF Yield
-102.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-136.8%
ROA
-87.0%
ROIC
-110.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-2.5M | $-2.4M | $— | — |
| Q4 null | $0.00 | NaN% | $-3.1M | $-3.1M | $— | — |
| FY null | $0.00 | -Infinity% | $-12.0M | $-11.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-2.7M | $-2.7M | $— | — |
| Q2 null | $0.00 | NaN% | $-2.7M | $-2.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-3.4M | $-3.3M | $— | — |
| Q4 null | $0.00 | NaN% | $-3.2M | $-3.2M | $— | — |
| FY null | $0.00 | NaN% | $-16.6M | $-16.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-3.6M | $-3.5M | $— | — |
| Q2 null | $0.00 | NaN% | $-5.1M | $-5.0M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-4.7M | $-4.6M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-3.4M | $-3.2M | $-5.75 | — |